View in EDS

Prospective phase II clinical trial of molecular glioblastoma (historical grade 2 and 3 IDH wildtype gliomas) preliminary novel exploratory analyses : Treatment intensification, margin reduction and epigenetic stratified outcomes with radiation therapy and chemotherapy.

Saved in:
Bibliographic Details
Title: Prospective phase II clinical trial of molecular glioblastoma (historical grade 2 and 3 IDH wildtype gliomas) preliminary novel exploratory analyses : Treatment intensification, margin reduction and epigenetic stratified outcomes with radiation therapy and chemotherapy.
Authors: Yeboa DN; Department of Radiation Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, USA. dnyeboa@mdanderson.org.; 1515 Holcombe Blvd, Unit 97, Houston, TX, 77030, USA. dnyeboa@mdanderson.org., Whitfield BT; Departments of Pathology and Translational Molecular Pathology, University of Texas MD Anderson Cancer Center, Houston, TX, USA., Lin R; Department of Radiation Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, USA., Ejezie CL; Department of Health Sciences, Towson University, Towson, MD, USA., Swanson TA; Department of Radiation Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, USA., Beckham TH; Department of Radiation Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, USA., Wang C; Department of Radiation Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, USA., De B; Department of Radiation Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, USA., Perni S; Department of Radiation Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, USA., Tom MC; Department of Radiation Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, USA., Li J; Department of Radiation Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, USA., McGovern SL; Department of Radiation Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, USA., Harrison R; Division of Neurology, University of British Columbia, Vancouver, Canada., Majd NK; Department of Neuro-Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, USA., Puduvalli VK; Department of Neuro-Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, USA., Aaroe AE; Department of Neuro-Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, USA., Loghin M; Department of Neuro-Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, USA., O'Brien BJ; Department of Neuro-Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, USA., Patel AD; Department of Neuro-Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, USA., Patel CB; Department of Neuro-Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, USA., Wefel JS; Department of Neuro-Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, USA., Taslicay CA; Quantitative Imaging Analysis Core, University of Texas MD Anderson Cancer Center, Houston, TX, USA., Gule-Monroe M; Department of Neuroradiology, University of Texas MD Anderson Cancer Center, Houston, TX, USA., Paulino AC; Department of Radiation Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, USA., McAleer MF; Department of Radiation Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, USA., Grosshans DR; Department of Radiation Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, USA., Ghia AJ; Department of Radiation Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, USA., Jiang W; Department of Radiation Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, USA., Chung C; Department of Radiation Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, USA., Maor M; Department of Radiation Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, USA., Yang CH; Department of Biostatistics, Yale University, New Haven, CT, USA., Gubbiotti MA; Departments of Pathology and Translational Molecular Pathology, University of Texas MD Anderson Cancer Center, Houston, TX, USA., Kamiya-Matsuoka C; Department of Neuro-Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, USA., Ballester LY; Departments of Pathology and Translational Molecular Pathology, University of Texas MD Anderson Cancer Center, Houston, TX, USA., Weathers SP; Department of Neuro-Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, USA., Huse JT; Departments of Pathology and Translational Molecular Pathology, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Source: Journal of neuro-oncology [J Neurooncol] 2025 Nov 05; Vol. 176 (1), pp. 72. Date of Electronic Publication: 2025 Nov 05.
Publication Type: Journal Article; Clinical Trial, Phase II
Journal Info: Publisher: Springer Country of Publication: United States NLM ID: 8309335 Publication Model: Electronic Cited Medium: Internet ISSN: 1573-7373 (Electronic) Linking ISSN: 0167594X NLM ISO Abbreviation: J Neurooncol Subsets: MEDLINE
Database: MEDLINE Ultimate
FullText Text:
  Availability: 0
Header DbId: mdl
DbLabel: MEDLINE Ultimate
An: 41191157
AccessLevel: 2
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: Prospective phase II clinical trial of molecular glioblastoma (historical grade 2 and 3 IDH wildtype gliomas) preliminary novel exploratory analyses : Treatment intensification, margin reduction and epigenetic stratified outcomes with radiation therapy and chemotherapy.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AU" term="%22Yeboa+DN%22">Yeboa DN</searchLink>; Department of Radiation Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, USA. dnyeboa@mdanderson.org.; 1515 Holcombe Blvd, Unit 97, Houston, TX, 77030, USA. dnyeboa@mdanderson.org.<br /><searchLink fieldCode="AU" term="%22Whitfield+BT%22">Whitfield BT</searchLink>; Departments of Pathology and Translational Molecular Pathology, University of Texas MD Anderson Cancer Center, Houston, TX, USA.<br /><searchLink fieldCode="AU" term="%22Lin+R%22">Lin R</searchLink>; Department of Radiation Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, USA.<br /><searchLink fieldCode="AU" term="%22Ejezie+CL%22">Ejezie CL</searchLink>; Department of Health Sciences, Towson University, Towson, MD, USA.<br /><searchLink fieldCode="AU" term="%22Swanson+TA%22">Swanson TA</searchLink>; Department of Radiation Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, USA.<br /><searchLink fieldCode="AU" term="%22Beckham+TH%22">Beckham TH</searchLink>; Department of Radiation Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, USA.<br /><searchLink fieldCode="AU" term="%22Wang+C%22">Wang C</searchLink>; Department of Radiation Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, USA.<br /><searchLink fieldCode="AU" term="%22De+B%22">De B</searchLink>; Department of Radiation Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, USA.<br /><searchLink fieldCode="AU" term="%22Perni+S%22">Perni S</searchLink>; Department of Radiation Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, USA.<br /><searchLink fieldCode="AU" term="%22Tom+MC%22">Tom MC</searchLink>; Department of Radiation Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, USA.<br /><searchLink fieldCode="AU" term="%22Li+J%22">Li J</searchLink>; Department of Radiation Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, USA.<br /><searchLink fieldCode="AU" term="%22McGovern+SL%22">McGovern SL</searchLink>; Department of Radiation Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, USA.<br /><searchLink fieldCode="AU" term="%22Harrison+R%22">Harrison R</searchLink>; Division of Neurology, University of British Columbia, Vancouver, Canada.<br /><searchLink fieldCode="AU" term="%22Majd+NK%22">Majd NK</searchLink>; Department of Neuro-Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, USA.<br /><searchLink fieldCode="AU" term="%22Puduvalli+VK%22">Puduvalli VK</searchLink>; Department of Neuro-Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, USA.<br /><searchLink fieldCode="AU" term="%22Aaroe+AE%22">Aaroe AE</searchLink>; Department of Neuro-Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, USA.<br /><searchLink fieldCode="AU" term="%22Loghin+M%22">Loghin M</searchLink>; Department of Neuro-Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, USA.<br /><searchLink fieldCode="AU" term="%22O'Brien+BJ%22">O'Brien BJ</searchLink>; Department of Neuro-Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, USA.<br /><searchLink fieldCode="AU" term="%22Patel+AD%22">Patel AD</searchLink>; Department of Neuro-Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, USA.<br /><searchLink fieldCode="AU" term="%22Patel+CB%22">Patel CB</searchLink>; Department of Neuro-Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, USA.<br /><searchLink fieldCode="AU" term="%22Wefel+JS%22">Wefel JS</searchLink>; Department of Neuro-Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, USA.<br /><searchLink fieldCode="AU" term="%22Taslicay+CA%22">Taslicay CA</searchLink>; Quantitative Imaging Analysis Core, University of Texas MD Anderson Cancer Center, Houston, TX, USA.<br /><searchLink fieldCode="AU" term="%22Gule-Monroe+M%22">Gule-Monroe M</searchLink>; Department of Neuroradiology, University of Texas MD Anderson Cancer Center, Houston, TX, USA.<br /><searchLink fieldCode="AU" term="%22Paulino+AC%22">Paulino AC</searchLink>; Department of Radiation Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, USA.<br /><searchLink fieldCode="AU" term="%22McAleer+MF%22">McAleer MF</searchLink>; Department of Radiation Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, USA.<br /><searchLink fieldCode="AU" term="%22Grosshans+DR%22">Grosshans DR</searchLink>; Department of Radiation Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, USA.<br /><searchLink fieldCode="AU" term="%22Ghia+AJ%22">Ghia AJ</searchLink>; Department of Radiation Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, USA.<br /><searchLink fieldCode="AU" term="%22Jiang+W%22">Jiang W</searchLink>; Department of Radiation Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, USA.<br /><searchLink fieldCode="AU" term="%22Chung+C%22">Chung C</searchLink>; Department of Radiation Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, USA.<br /><searchLink fieldCode="AU" term="%22Maor+M%22">Maor M</searchLink>; Department of Radiation Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, USA.<br /><searchLink fieldCode="AU" term="%22Yang+CH%22">Yang CH</searchLink>; Department of Biostatistics, Yale University, New Haven, CT, USA.<br /><searchLink fieldCode="AU" term="%22Gubbiotti+MA%22">Gubbiotti MA</searchLink>; Departments of Pathology and Translational Molecular Pathology, University of Texas MD Anderson Cancer Center, Houston, TX, USA.<br /><searchLink fieldCode="AU" term="%22Kamiya-Matsuoka+C%22">Kamiya-Matsuoka C</searchLink>; Department of Neuro-Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, USA.<br /><searchLink fieldCode="AU" term="%22Ballester+LY%22">Ballester LY</searchLink>; Departments of Pathology and Translational Molecular Pathology, University of Texas MD Anderson Cancer Center, Houston, TX, USA.<br /><searchLink fieldCode="AU" term="%22Weathers+SP%22">Weathers SP</searchLink>; Department of Neuro-Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, USA.<br /><searchLink fieldCode="AU" term="%22Huse+JT%22">Huse JT</searchLink>; Departments of Pathology and Translational Molecular Pathology, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%228309335%22">Journal of neuro-oncology</searchLink> [J Neurooncol] 2025 Nov 05; Vol. 176 (1), pp. 72. <i>Date of Electronic Publication: </i>2025 Nov 05.
– Name: TypePub
  Label: Publication Type
  Group: TypPub
  Data: Journal Article; Clinical Trial, Phase II
– Name: TitleSource
  Label: Journal Info
  Group: Src
  Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Springer%22">Springer </searchLink><i>Country of Publication: </i>United States <i>NLM ID: </i>8309335 <i>Publication Model: </i>Electronic <i>Cited Medium: </i>Internet <i>ISSN: </i>1573-7373 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%220167594X%22">0167594X </searchLink><i>NLM ISO Abbreviation: </i>J Neurooncol <i>Subsets: </i>MEDLINE
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=41191157
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1007/s11060-025-05269-6
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        StartPage: 72
    Titles:
      – TitleFull: Prospective phase II clinical trial of molecular glioblastoma (historical grade 2 and 3 IDH wildtype gliomas) preliminary novel exploratory analyses : Treatment intensification, margin reduction and epigenetic stratified outcomes with radiation therapy and chemotherapy.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Yeboa DN
      – PersonEntity:
          Name:
            NameFull: Whitfield BT
      – PersonEntity:
          Name:
            NameFull: Lin R
      – PersonEntity:
          Name:
            NameFull: Ejezie CL
      – PersonEntity:
          Name:
            NameFull: Swanson TA
      – PersonEntity:
          Name:
            NameFull: Beckham TH
      – PersonEntity:
          Name:
            NameFull: Wang C
      – PersonEntity:
          Name:
            NameFull: De B
      – PersonEntity:
          Name:
            NameFull: Perni S
      – PersonEntity:
          Name:
            NameFull: Tom MC
      – PersonEntity:
          Name:
            NameFull: Li J
      – PersonEntity:
          Name:
            NameFull: McGovern SL
      – PersonEntity:
          Name:
            NameFull: Harrison R
      – PersonEntity:
          Name:
            NameFull: Majd NK
      – PersonEntity:
          Name:
            NameFull: Puduvalli VK
      – PersonEntity:
          Name:
            NameFull: Aaroe AE
      – PersonEntity:
          Name:
            NameFull: Loghin M
      – PersonEntity:
          Name:
            NameFull: O'Brien BJ
      – PersonEntity:
          Name:
            NameFull: Patel AD
      – PersonEntity:
          Name:
            NameFull: Patel CB
      – PersonEntity:
          Name:
            NameFull: Wefel JS
      – PersonEntity:
          Name:
            NameFull: Taslicay CA
      – PersonEntity:
          Name:
            NameFull: Gule-Monroe M
      – PersonEntity:
          Name:
            NameFull: Paulino AC
      – PersonEntity:
          Name:
            NameFull: McAleer MF
      – PersonEntity:
          Name:
            NameFull: Grosshans DR
      – PersonEntity:
          Name:
            NameFull: Ghia AJ
      – PersonEntity:
          Name:
            NameFull: Jiang W
      – PersonEntity:
          Name:
            NameFull: Chung C
      – PersonEntity:
          Name:
            NameFull: Maor M
      – PersonEntity:
          Name:
            NameFull: Yang CH
      – PersonEntity:
          Name:
            NameFull: Gubbiotti MA
      – PersonEntity:
          Name:
            NameFull: Kamiya-Matsuoka C
      – PersonEntity:
          Name:
            NameFull: Ballester LY
      – PersonEntity:
          Name:
            NameFull: Weathers SP
      – PersonEntity:
          Name:
            NameFull: Huse JT
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 05
              M: 11
              Text: 2025 Nov 05
              Type: published
              Y: 2025
          Identifiers:
            – Type: issn-electronic
              Value: 1573-7373
          Numbering:
            – Type: volume
              Value: 176
            – Type: issue
              Value: 1
          Titles:
            – TitleFull: Journal of neuro-oncology
              Type: main
ResultId 1